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Abstract
Background: Chronic obstructive pulmonary disease (COPD) remains a major health problem, strongly related to
smoking. Despite the publication of practice guidelines on prevention and treatment, not all patients with the
disease receive the recommended healthcare, particularly with regard to smoking cessation advice where
applicable. We have developed a tailored implementation strategy for enhancing general practitioners’ adherence
to the disease management guidelines. The primary aim of the study is to evaluate the effects of this tailored
implementation intervention on general practitioners’ adherence to guidelines.
Methods/Design: A pragmatic two-arm cluster randomized trial has been planned to compare care following the
implementation of tailored interventions of four recommendations in COPD patients against usual care. The study
will involve 18 general practices (9 in the intervention group and 9 in the control group) in Poland, each with at
least 80 identified (at the baseline) patients with diagnosed COPD. The nine control practices will provide usual care
without any interventions. Tailored interventions to implement four recommendations will be delivered in the
remaining nine practices. At follow-up after nine months, data will be collected for all 18 general practices. The
primary outcome measure is physicians’ adherence to all four recommendations: brief anti-smoking advice, dyspnea
assessment, care checklist utilization and demonstration to patients of correct inhaler use. This measurement will be
based on data extracted from identified patients’ records. Additionally, we will survey and interview patients with
chronic obstructive pulmonary disease about the process of care.
Discussion: The results of this trial will be directly applicable to primary care in Poland and add to the growing
body of evidence on interventions to improve chronic illness care.
Trial registration: This trial has been registered with Clinical Trials Protocol Registration System. Trial number:
NCT01893476.
Keywords: Chronic obstructive pulmonary disease, Implementation science, Primary health care
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Background
Chronic obstructive pulmonary disease (COPD) remains
a major health problem. Worldwide it has been ranked
as the sixth leading cause of death for both genders [1].
In 2020 COPD is projected to rank fifth worldwide in bur-
den of disease. It is also projected to be the fourth leading
cause of death worldwide by 2030 due to an increase in
smoking rates and demographic changes in many coun-
tries [2]. A national survey conducted in Poland in 2007
indicated that 34% of men smoked daily, 2% were occa-
sional smokers, 19% were former smokers and 45% had
never smoked. In women these percentages were 23, 3, 10
and 64% respectively [3].
Epidemiological studies of COPD on a representative
sample have not been performed in Poland, but esti-
mates from smaller studies suggested a relatively high
prevalence. Studies in selected geographical areas found
that signs and symptoms of COPD were seen in about
10% of patients over 40-years old [4]. Studies in large
cities in Poland showed a 9.8% prevalence of COPD in
populations between 41 and 72 years old [5]. These data
are similar to other European data, describing preva-
lence rates of 4 to 11% in adults in Europe [6]. The total
number of people suffering from COPD in Poland is es-
timated to be about 2 million (on a population of 38
million inhabitants). This places COPD as the third most
frequent chronic illness, and it is the fourth most com-
mon cause of death in Poland [7].
In Poland, most COPD patients are treated in primary
care, which is the entry point to the public health care
system. The system is based on compulsory health insur-
ance, managed by the National Health Fund (NHF), which
purchases health services from physicians and health care
enterprises. Patients register with a particular primary care
practice, signing on to an individual general practitioner’s
list of patients, and can be referred for specialist out-
patient consultation or to a hospital, if needed. Ambula-
tory care (primary and out-patient specialist services) is
provided by therapeutic entities (clinics or dispensaries)
and by medical practices. Rehabilitation and long-term
care are provided within both the health care sector and
the social care sector, but coordination between the two is
poor. Furthermore, limited financial resources available to
the NHF and shortages of medical personnel have nega-
tive effects on access to health care services [8].
There is no national consensus on the care paths for
COPD, and various guidelines on COPD are used, some
of which national and some international [9,10]. However,
the guidelines in use share most of recommendations that
we have identified and prioritized for the purpose of this
trial. There is very little evidence on the degree of adher-
ence to the guidelines for the management of COPD used
by Polish physicians. One study, which evaluated the NHF
funded COPD prevention program aiming to reduce the
incidence and disability related to COPD by complex
educational, diagnostic and therapeutic interventions in
people at risk, showed low rates of participation of pri-
mary health care providers despite additional funding. An
interesting finding was that the extent of program com-
pletion was strongest for qualified general practitioners
compared to physicians without specialty training or
non-generalists: internal diseases specialists and pedia-
tricians working at primary care setting [11].
It is unclear whether studies on the implementation
of evidence-based recommendations for primary care in
COPD patients from countries with well-developed primary
care systems, like the United Kingdom and the Netherlands
[12,13] can be translated to Poland. In searching the Polish
medical literature, we did not find published research on
the implementation of COPD guidelines or recommen-
dations in Poland. The authors identified three papers
with results partially related to the subject of this study
[14-16]. These found that 30% of patients with the diag-
nosis do not fulfill criteria for COPD, in 15% of cases
spirometry had not been performed, and more than 70%
of patients received inhaled steroids. Such findings sug-
gest that adherence to diagnostic and management rec-
ommendations are inadequate.
Preliminary qualitative evidence from the authors’ earl-
ier work showed that not one single guideline for COPD
was used by all GPs or medical specialists. However, re-
sponders pointed out the individual recommendations
most commonly used and the barriers to their implemen-
tation. The identified barriers for adhering to specific rec-
ommendations were: (1) lack of knowledge on smoking
cessation brief intervention, (2) dyspnea evaluation tool
was unavailable, (3) lack of a care plan, and (4) lack of
demonstration-inhaling devices. Other research has indi-
cated that the treatment parameters from the (COPD)
guidelines are not always measured [17-19]. The conse-
quence is that not all patients receive recommended ad-
vice and treatment from their physicians.
This study is part of the Tailored Implementation for
Chronic Diseases (TICD) international collaborative re-
search project, which is being undertaken in Germany,
Norway, Poland, the Netherlands and the United Kingdom.
The aim is to develop and test methods of tailoring
knowledge-implementation interventions to determinants
of practice in chronic illness care [20]. In Poland, the focus
is on the implementation of COPD guidelines in primary
care. The research group in Poland selected four key rec-
ommendations applicable to primary care (Table 1) from
the four COPD guidelines most relevant to primary care
and used in Poland.
Objective
The objective of this study is to examine the effective-
ness of a tailored implementation strategy for enhancing
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physicians’ adherence to four recommendations for the
management of COPD patients in primary care. The
process of tailoring implementation interventions and
the impact on the effectiveness of the strategy will also
be studied.
Research questions
The questions we will be attempting to address in this
study are as follows: what is the effectiveness of a tai-
lored implementation strategy compared to usual care in
enhancing primary care physicians’ adherence to guide-
lines?, and how do the determinants of practice targeted
by the tailored implementation strategy change over
time, and how does their variability relate to the effect-
iveness of implementation strategies?
Methods/design
Study design
This study is a two-arm pragmatic, cluster randomized
trial (CRCT) [21,22], which compares a tailored inter-
vention program directed at general practitioners with
usual primary care. It is localized in Lodz, the third lar-
gest city in Poland, with a population of about 750.000
inhabitants with broadly average mortality and morbid-
ity, although specific health data are lacking. It aims to
include general practices with adult patients with COPD
under their care. The general practices will be random-
ized into two equally sized groups
Sample size calculation
The sample size calculation indicated that, for a two-arm
cluster controlled randomized trial, a minimum number
of 16 primary care practices with minimum of 30 COPD
patients per practice is required. A total of 16 clusters and
at least 480 subjects is required at baseline and follow-up
(8 clusters in each study arm) to detect a difference, or
change in adherence, of between 40% and 60% with se-
lected COPD recommendations, between the intervention
group (facilitating adherence to guidelines) and the con-
trol group without intervention (usual care), with 80%
power, a two-tailed alpha of 0.05, and intra-cluster correl-
ation of 0.05.
A standard sample size formula was used to calculate
the initial unadjusted sample size requirements, followed
by appropriate adjustment for clustering by general prac-
tice according to Campbell et al. [23], with expected
small clustering effect (ICC = 0.05). Previous reported
ICCs vary from 0.03 for smoking advice [23] to 0.05 for
cluster randomized trials in primary care (data from
Trial of Older People in the Community) [24,25]. It was
decided to increase the sample by 10% to account for
contingencies such as non-response or recording error,
giving a total of 18 practices.
With regard to the number of patients with COPD per
practice, an assumed response rate of 58% [26,27] and a
dropout of 35% [28], which led to a total of 80 COPD
patients needed per general practice at baseline. Patients
will be selected via the medical records using ICD code
J44, and medical records will be labelled at the baseline
of the study.
Setting and participants
General practices
Eighteen general practices selected with random sampling
within the Lodz region of Poland, with 80 or more regis-
tered COPD patients each (identified via J44 ICD-10), will
be invited to participate in the study. The baseline number
of COPD patients is determined by assumed response rate
and dropout described above, to assure at least 30 at
follow-up. Some of the practices were previously involved
in other studies and have an established agreement with
the Medical University of Lodz in the field of research and
vocational training. The main study has been planned to
take place between December 2013 and September 2014.
After having given informed consent, primary care prac-
tices will be randomly allocated to one of two groups. The
medical records of patients with COPD will be labelled
with blue stickers at the baseline of the study (Figure 1).
General practitioners
All GPs working in targeted practices are required to
participate in the study.
Eligibility criteria
Patients
Eligible patients will be approached at follow-up. Only
patients who were treated in the same practice at baseline
(with the labelled medical records) will be considered for
inclusion so that the study is prospective. Exclusion cri-
teria are: (1) terminal illness and (2) cognitive impair-
ments. At follow up 80 patients, randomly selected (with
personal data unknown to researchers) will receive an in-
formed consent form and an invitational letter via their
GPs, and will be asked to fill in a questionnaire and/or
participate in an audio taped interview or focus group.
This letter will provide comprehensive information about
Table 1 Key recommendations for COPD management
A Brief smoking cessation counseling is effective and every tobacco
user should be offered stop-smoking advice at every contact with
health care providers.
B The prognosis of COPD should be estimated using the mMRC
dyspnea scale.
C The patient should be given the basic information about his/her
disease, its treatment and the expected effects of applied drugs,
in order to enhance that the patient takes an active, participating
role in the long-term treatment.
D The patient should be trained in the correct use of all devices
which he/she will use for inhalation.
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the study. Contact details of the researchers will be pro-
vided so that patients can ask questions. Patients’ informa-
tion gathered from questionnaires or from interviews will
be anonymized.
Randomization
Randomization will be performed by a statistician not
involved in the trial, through a computer. The general
practices will be allocated randomly to two equally sized
groups: an intervention group and a control group. At
the end of the study a group of patients will be randomly
selected in order to invite them to fill out the end-of-
study questionnaire. Participants in this trial will not be
blinded. Descriptive statistics and logistic regression will
be used for analyzing the data. The level of statistical
significance will be p < 0.05.
Blinding
COPD patients within each participating intervention
and control practice will be identified at the baseline. Be-
cause of the nature of the intervention, it is not possible
to blind GP participants (in practices).
Outcome assessment will not be blinded as the research
assistants will be aware of practice group allocation, and
the data analysis will be performed by researchers and a
statistician blinded to the study group.
Implementation program
The implementation program is based on multiphase re-
search performed in the TICD project. In the first phase
has identified barriers and enablers for improving COPD
care, focusing on the four recommendations selected. One
hundred and sixty determinants were listed, grouped (ac-
cording to the TICD checklist domains [29]), and judged
by our research team on importance and changeability
using Likert scales. The result was 24 determinants of
practice. The second phase of the project, identified deter-
minants were prioritized during focus group discussions
and matched to implementation strategies. The final deci-
sions on the interventions matched to the determinants
for four recommendations are presented in Table 2. This
procedure led to the following implementation program.
Smoker identification and brief intervention
First, participating physicians will receive training in brief
smoking status identification and anti-smoking counsel-
ling, and will be asked to record information about the
actions they perform in patients’ medical records. This
intervention will address the recommendation of Global
P
Baseline data collection 18 practices randomised with 80 COPD patiens each
Study group: 9 practices Control group: 9 practices
End of the study data collection
Questionnaire for GPs
Review of patient’s history
Questionnaire for patients
P P P P P P PP
Interviews Focus Groups
Figure 1 Flowchart for CRCT.
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Initiative for Chronic Obstructive Lung Disease (GOLD)
based on Wilson et al. [30].
Dyspnea evaluation
Second, an additional form containing the modified Med-
ical Research Council Dyspnea Scale (mMRC) will be
inserted into patients’ medical records on paper. It is a
validated patient symptom questionnaire for a subjective
assessment of COPD symptoms. This intervention will ad-
dress the recommendation of National Institute for Health
and Care Excellence based on Fletcher et al. [31].
GPs will be asked to determine the patient’s status ac-
cording to the scale and put this information into the
patient’s medical records.
COPD check list
Third, a checklist for practitioners will be provided with
information about what should be done while consulting
on a patient with COPD. This intervention will address
the recommendation of the European Respiratory Soci-
ety [32]. It will cover points such as that a patient should
be given basic information about COPD, its treatment,
and the expected effects of applied drugs, making the
patient an active, aware participant in their long-term
treatment. GPs will be asked to provide patients with the
information and tick a box if it is done.
Demonstration inhaler devices
Finally, practices will be provided with training inhaler
device sets for health care staff and train GPs on how to
instruct patients to use devices properly. This interven-
tion will address the recommendation of the Polish Soci-
ety of Lung Diseases [33].
GPs will be asked to teach patients in the correct use
of each device and record information about the fact in
patient’s medical records.
Control group
In this arm, GPs will provide their usual care for COPD
patients. The practices in the control group will receive
feedback after the end of the study about their own
performance in comparison with the performance of
other practices in the study in relation to the guideline
recommendations. The GPs will receive no intervention
during the study.
Outcomes/measures
Primary outcome
The primary outcome will be the GPs’ adherence to the
recommendations, which is dichotomized as follows. A
positive score is given if all recommendations are followed,
while following less than four recommendations is given a
negative score. Data listed in Table 3 will be obtained from
the patients’ medical records (independent of the checklist
that is provided as part of the intervention) and during in-
terviews. All identified COPD patients who gave informed
consent in each practice will be included, and full data
protection procedures will be followed.
Secondary outcomes
The secondary outcome will be patient reported health
status. We will review COPD patients’ medical records
to measure health outcomes such as a change in smok-
ing status, the quantity of COPD medications prescribed,
dyspnea perception and number of exacerbations in the
past and over the study period.
Process evaluation
All aspects of the coordinated process evaluation will be
implemented in this study, following the international
study protocol for the TICD project, in order to identify
determinants of change in chronic illness care, to exam-
ine the validity of the tailoring methods that were ap-
plied, and to analyze the association of implementation
activities with the effectiveness of the program [34]. The
process evaluation will comprise three main components:
a structured survey with health professionals in the trials,
semi-structured interviews with a purposeful sample of
this study population, and standardized documentation of
organizational practice characteristics. The evaluation will
be guided by ‘logic models’ of the implementation pro-
grams: frameworks that specify the linkages between the
strategies used, the determinants addressed by tailoring,
and the anticipated outcomes.
A written survey will be undertaken involving participat-
ing health professionals. The questionnaire will list the
Table 2 Identified determinants and interventions for selected recommendations
Recommendation Determinant Proposed intervention(s)
A A brief clinician’s counseling to quit smoking Additional training for GPs Labeling medical records for COPD patients and training GPs
in brief intervention
B The prognosis of COPD should be estimated
using mMRC dyspnea scale
Prepared form Additional form (in paper or in computer medical records) with
mMRC scale
C The patient should be given the basic
information about his/her disease
Checklist in medical history Providing physicians with a checklist in patients’ records to facilitate
what should be done during consultation
D The patient has to be trained in the correct
use of all devices
Inhaling devices for training To provide GPs’ clinics with training inhaler devices to show
patient’s how to use them
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determinants of practice, which were identified and priori-
tized in an earlier phase of the TICD project, respondents
being asked to assess whether the program successfully
targeted them. A free text field will be used to identify
possible other determinants. The survey will also contain
questions on the actual implementation activities that
took place, to record the extent to which the target group
used the offered interventions, and any adaptions made in
the delivery phase of the implementation program. The
core components of the implementation program will be
specified. For each of the core components, content, dur-
ation, frequency and coverage will be recorded in a struc-
tured way. The content, duration, frequency and coverage
aspects of intervention fidelity will also be covered. A free
text field will be added to identify strategies which have
been missed in the tailoring process, allowing the evalu-
ation of the methods used for tailoring.
The face-to-face or telephone interviews will be per-
formed with a purposive sample of health professionals.
Interim analysis after five to ten interviews will be per-
formed to adapt the interview format and purposeful
sampling scheme as required.
Data collection
At the end of the study data will be collected by review
of medical records of COPD patients identified at the
baseline who visited their GPs during the last nine
months. Extracted information will cover the follow-
ing: brief anti-smoking advice performed, information
about dyspnea, COPD checklist utilization and training
on using inhalers.
Patients with COPD who have given signed informed
consent will be asked to fill in a questionnaire and par-
ticipate in an interview containing questions about the
process of care, information received from GPs and pa-
tients’ health status perception.
Statistical methods
The primary analysis will be on an intention to treat
basis. Missing values will be inputted with a multiple im-
putation method. Data will be coded, cleaned and locked
before any analyses are made. Quantitative data will be
analyzed in aggregate, using the Statistical Package for
the Social Sciences (SPSS, (version 17, IBM Corp.) and
Statistica (v10, StatSoft Inc.). Study groups will be com-
pared with respect to the determinants of COPD and its
improvement. Only members of the research team who
need access to the database to fulfill their roles within the
study will be granted access to the database. Demographic
characteristics of the practices and the participants within
the practices will be described using percentages, mea-
sures of central tendency (means or medians) and mea-
sures of variation (standard deviations or ranges). The
analysis will be based on the patients nested within prac-
tices two-level model. The primary endpoint is the GPs
adherence to four COPD guidelines after nine months, in
each practice. Secondary endpoints are the change in
smoking status and health care utilization during the nine
months amongst included patients. Data will be compared
between arms using logistic regression (with logit link
function and binomial distribution) with patient at level
one and practice at level two. The ICC and odds ratios
and 95% confidence intervals will be estimated using two-
level random intercepts logistic regression models. The
significance level will be set at α = 0.05 for all analyses.
Ethical approval
This study has been approved by the Bioethical Committee
of Medical University of Lodz, Poland (reference RNN/
491/13/KB of 18 June 2013).
Discussion
COPD care improvement in primary care has not been
studied extensively. Schermer et al. observed a small
and late effect of e-learning and repeated feedback on
the quality of spirometry as performed by family practice
nurses [35]. Kennedy et al. studied at practice-level train-
ing in a whole systems approach to self-management sup-
port for patients with chronic conditions and found no
statistically significant differences between patients attend-
ing trained practices and those attending control practices,
although this study looked at three conditions simultan-
eously (diabetes, COPD and irritable bowel syndrome)
[36]. While these trials focused on specific aspects of
COPD care (spirometry and self-management education,
respectively), the intervention program in this study in-
tends to improve COPD care more broadly.
Meulepas et al. studied the effect of a primary care
model that included smoking cessation, inhaler technique
training and dyspnea scoring according to the MRC scale
[12]. V an den Bemt et al. also studied guideline based
COPD-management in primary care [13]. However their
interventions were at least partly directed at patients,
while this study targets general practitioners. This study is
probably the first randomized trial of a tailored implemen-
tation program for improving primary care for patients
with chronic illness in an East European country. The
study has some limitations, such as possible selection bias
since practices with less than 80 COPD patients were
excluded as well as those that have some GPs teachers.
Table 3 Information recorded in patients’ records to
determine adherence of a GP the recommendations
1. Brief anti-smoking counselling performed
2. Dyspnea assessed
3. Management process of COPD assessed
4. Training patient on correct use of inhaling device performed.
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Nevertheless, it is the authors’ belief that the results will
be directly relevant and applicable to primary care in
Poland. If the implementation program is effective, then
wide-scale application would be warranted.
Trial status
Registration has been completed, general practices have
been recruited and randomized, and interventions
delivered.
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